Shandong Xinhua Pharmaceutical Company Limited (Shandong Xinhua) filed its Monthly Return for the period ended 31 August 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised / Registered Share Capital • H Shares: 195.00 million shares at RMB 1 par value; no change from July 2026. • A Shares: 501.68 million shares at RMB 1 par value; no change from July 2026. • Aggregate authorised/registered share capital stood at RMB 696.68 million.

Issued Shares and Public Float • H Shares (Stock Code 00719): 195.00 million in issue; zero treasury shares. The company affirmed compliance with the Main Board’s 5 % minimum public-float requirement for PRC issuers with H-share listings. • A Shares: 501.68 million in issue; zero treasury shares. • No increases, decreases, or treasury share movements were recorded for either share class in August.

Equity Incentive Plans • 2021 A-Share Option Scheme: 1.16 million options remained outstanding at month-end, unchanged from July. No options were exercised; consequently, no new shares were issued and no funds were raised.

Other Capital Instruments • The company reported no outstanding warrants, convertible securities, or other share-issuance arrangements. • There were no additional movements in treasury shares.

Compliance Confirmation Shandong Xinhua’s board and company secretary affirmed that all share-related activities during the month adhered to Hong Kong Stock Exchange listing rules and applicable regulations.

With all headline figures static and regulatory compliance confirmed, Shandong Xinhua enters September 2026 maintaining a total of 696.68 million authorised shares and 696.68 million issued shares across its A and H classes.